Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | NQO2 | P16083 | 5/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407380 | 0.71 | MTNR1A (0.57) | ESR1NQO2MTNR1AMTNR1BMAOA | |
| SCHEMBL3407376 | 0.71 | MTNR1A (0.57) | ESR1NQO2MTNR1AMTNR1BMAOA | |
| SCHEMBL3412841 | 0.71 | MTNR1A (0.57) | ESR1NQO2MTNR1AMTNR1BMAOA | |
| SCHEMBL3433701 | 0.69 | TRPV1 (0.49) | TRPV1ESR1NQO2MTNR1AMTNR1B | |
| SCHEMBL3411168 | 0.69 | TRPV1 (0.49) | TRPV1ESR1NQO2MTNR1AMTNR1B | |
| SCHEMBL3411164 | 0.69 | TRPV1 (0.49) | TRPV1ESR1NQO2MTNR1AMTNR1B | |
| SCHEMBL13424161 | 0.69 | MTNR1A (0.48) | TRPV1ESR1NQO2MTNR1AMTNR1B | |
| SCHEMBL7555403 | 0.68 | DRD3 (0.46) | OPRM1 | |
| SCHEMBL981045 | 0.68 | ITGB3 (0.50) | ESR1OPRM1OPRD1 | |
| SCHEMBL538079 | 0.68 | ITGB3 (0.39) | NQO2MTNR1AMTNR1BOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368566-B2 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060194786-A1 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194786-A1 | Process and intermediates for preparing benzazepines | CYP2E1, CYP1B1, CYP3A4 | TRPV1 536/4885ESR1 966/4885NQO2 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.